Start:
February 2012
End:
October 2013
Enrollment:
100
This Phase I clinical trial will evaluate the safety and pharmacodynamic effects of the experimental drug BMS-241027 in people with mild Alzheimer's disease.
Minimum Age: 50 Years
Maximum Age: 90 Years
Contact study personnel listed either under the general study contact or the location nearest you.
Who Is the General Study Contact?
For information about U.S. sites, please call the telephone numbers in the chart below. For information about a site outside the United States, e-mail Clinical.Trials@bms.com. The first line of the e-mail must contain the clinical trials identifying number, NCT01492374, and the site number listed below. Only trial sites that are recruiting have contact information at this time.
Contact NIA’s Alzheimer’s and related Dementias Education and Referral (ADEAR) Center at 800-438-4380 or email ADEAR.
Lead: Bristol-Myers Squibb
Source: ClinicalTrials.gov ID: NCT01492374
An official website of the U.S. government, managed by the National Institute on Aging at the National Institutes of Health